Skip to main content

Articles

Page 3 of 103

  1. Preclinical and epidemiological studies indicate a potential chemopreventive role of low-density lipoprotein cholesterol (LDL-C) -lowering drugs in the risks of breast cancer and prostate cancer, but the causa...

    Authors: Lulu Sun, Huan Ding, Yiming Jia, Mengyao Shi, Daoxia Guo, Pinni Yang, Yu Wang, Fanghua Liu, Yonghong Zhang and Zhengbao Zhu
    Citation: Breast Cancer Research 2022 24:12
  2. Estrogen-receptor (ER) and progesterone-receptor (PR) expression levels in breast cancer, which have been principally compared via binomial descriptors, can vary widely across tumors. We sought to characterize...

    Authors: Grace Wei, Mingxiang Teng, Marilin Rosa and Xia Wang
    Citation: Breast Cancer Research 2022 24:11
  3. Breast cancer can recur months to decades after an initial diagnosis and treatment. The mechanisms that control tumor cell dormancy remain poorly understood, making it difficult to predict which patients will ...

    Authors: Qihao Ren, Weng Hua Khoo, Alexander P. Corr, Tri Giang Phan, Peter I. Croucher and Sheila A. Stewart
    Citation: Breast Cancer Research 2022 24:10
  4. Several anthropometric measures have been associated with hormone-related cancers, and it has been shown that estrogen metabolism in postmenopausal women plays an important role in these relationships. However...

    Authors: Ashley M. Geczik, Roni T. Falk, Xia Xu, Daniel Ansong, Joel Yarney, Beatrice Wiafe-Addai, Lawrence Edusei, Florence Dedey, Verna Vanderpuye, Nicholas Titiloye, Ernest Adjei, Francis Aitpillah, Ernest Osei-Bonsu, Joseph Oppong, Richard Biritwum, Kofi Nyarko…
    Citation: Breast Cancer Research 2022 24:9
  5. Triple-negative breast cancers (TNBC) have a relatively poor prognosis and responses to targeted therapies. Between 25 and 39% of TNBCs are claudin-low, a poorly differentiated subtype enriched for mesenchymal...

    Authors: Yu Hin Tang, Anja Rockstroh, Kamil A. Sokolowski, Layla-Rose Lynam, Melanie Lehman, Erik W. Thompson, Philip A. Gregory, Colleen C. Nelson, Marianna Volpert and Brett G. Hollier
    Citation: Breast Cancer Research 2022 24:8
  6. Keratins (KRTs) are intermediate filament proteins that interact with multiple regulatory proteins to initiate signaling cascades. Keratin 13 (KRT13) plays an important role in breast cancer progression and me...

    Authors: Lijuan Yin, Qinlong Li, Stefan Mrdenovic, Gina Chia-Yi Chu, Boyang Jason Wu, Hong Bu, Peng Duan, Jayoung Kim, Sungyong You, Michael S. Lewis, Gangning Liang, Ruoxiang Wang, Haiyen E. Zhau and Leland W. K. Chung
    Citation: Breast Cancer Research 2022 24:7
  7. Ductal carcinoma in situ (DCIS) of breast is the noninvasive lesion that has propensity to progress to the malignant form. At present, it is still unknown which lesions can potentially progress to invasive for...

    Authors: Ravindra Pramod Deshpande, Sambad Sharma, Yin Liu, Puspa Raj Pandey, Xinhong Pei, Kerui Wu, Shih-Ying Wu, Abhishek Tyagi, Dan Zhao, Yin-Yuan Mo and Kounosuke Watabe
    Citation: Breast Cancer Research 2022 24:6
  8. High participation in mammographic screening is essential for its effectiveness to detect breast cancers early and thereby, improve breast cancer outcomes. Breast density is a strong predictor of breast cancer...

    Authors: Sarah Pirikahu, Helen Lund, Gemma Cadby, Elizabeth Wylie and Jennifer Stone
    Citation: Breast Cancer Research 2022 24:5
  9. Breast cancer incidence differs between non-immigrants and immigrants from low- and middle-income countries. This study investigates whether immigrants also have different subtype-specific incidences.

    Authors: Kirsti V. Hjerkind, Anna L. V. Johansson, Cassia B. Trewin, Hege G. Russnes and Giske Ursin
    Citation: Breast Cancer Research 2022 24:4
  10. Frequent sugar-sweetened beverage (SSB) intake has been associated with indirect markers of breast cancer risk, such as weight gain in adolescents and early menarche. How SSB intake relates to breast compositi...

    Authors: Lara Yoon, Camila Corvalán, Ana Pereira, John Shepherd and Karin B. Michels
    Citation: Breast Cancer Research 2022 24:3
  11. Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how the...

    Authors: Thomas U. Ahearn, Haoyu Zhang, Kyriaki Michailidou, Roger L. Milne, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Michael Lush, Qin Wang, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Annelie Augustinsson, Adinda Baten…
    Citation: Breast Cancer Research 2022 24:2
  12. A growing body of evidence indicates that abnormal expression of circular RNAs (circRNAs) plays a crucial role by acting as molecular sponges of microRNAs (miRNAs) in various diseases, including cancer. In thi...

    Authors: Lingjiao Meng, Sheng Chang, Yang Sang, Pingan Ding, Liuxin Wang, Xixi Nan, Ruiyu Xu, Fei Liu, Lina Gu, Yang Zheng, Ziyi Li and Meixiang Sang
    Citation: Breast Cancer Research 2022 24:1
  13. The first aim of the study was to compare the scores and types of stromal immune cells in 30 patients with primary DCIS and in the same patients after invasive breast recurrence in order to assess possible dif...

    Authors: Anna Niwińska and Wojciech P. Olszewski
    Citation: Breast Cancer Research 2021 23:118
  14. The active thyroid hormone triiodothyronine (T3) has been found to have an estrogen-like effect on breast cancer cells. Thyroid hormone receptor alpha-2 (THRα-2) acts as an antagonist for triiodothyronine (T3)...

    Authors: Malte Sandsveden, Signe Borgquist, Ann H. Rosendahl and Jonas Manjer
    Citation: Breast Cancer Research 2021 23:117
  15. Triple-negative breast cancer (TNBC) is highly metastatic and lethal. Due to a lack of druggable targets for this disease, there are no effective therapies in the clinic.

    Authors: Mengli Zhang, Mei Meng, Yuxi Liu, Jindan Qi, Zhe Zhao, Yingnan Qiao, Yanxing Hu, Wei Lu, Zhou Zhou, Peng Xu and Quansheng Zhou
    Citation: Breast Cancer Research 2021 23:116
  16. Mounting evidence supports that long noncoding RNAs (lncRNAs) have critical roles during cancer initiation and progression. In this study, we report that the plasmacytoma variant translocation 1 (PVT1) lncRNA ...

    Authors: Shuiyi Liu, Weiqun Chen, Hui Hu, Tianzhu Zhang, Tangwei Wu, Xiaoyi Li, Yong Li, Qinzhi Kong, Hongda Lu and Zhongxin Lu
    Citation: Breast Cancer Research 2021 23:115
  17. The extent of cellular heterogeneity in breast cancer could have potential impact on diagnosis and long-term outcome. However, pathology evaluation is limited to biomarker immunohistochemical staining and morp...

    Authors: Alison Min-Yan Cheung, Dan Wang, Kela Liu, Tyna Hope, Mayan Murray, Fiona Ginty, Sharon Nofech-Mozes, Anne Louise Martel and Martin Joel Yaffe
    Citation: Breast Cancer Research 2021 23:114
  18. Triple negative breast cancer (TNBC) is more common in African American (AA) than Non-AA (NAA) population. We hypothesize that tumor microenvironment (TME) contributes to this disparity. Here, we use multiplex...

    Authors: Vesal Yaghoobi, Myrto Moutafi, Thazin Nwe Aung, Vasiliki Pelekanou, Sanam Yaghoubi, Kim Blenman, Eiman Ibrahim, Ioannis A. Vathiotis, Saba Shafi, Anup Sharma, Tess O’Meara, Aileen I. Fernandez, Lajos Pusztai and David L. Rimm
    Citation: Breast Cancer Research 2021 23:113
  19. About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low...

    Authors: Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Clemens Schmitt, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Christian Fridolin Singer, Florian Roitner, Christopher Hager, Johannes Andel, Michael Hubalek, Michael Knauer…
    Citation: Breast Cancer Research 2021 23:112
  20. Early age at breast development (thelarche) has been associated with increased breast cancer risk. Average age at thelarche has declined over time, but there are few established risk factors for early thelarch...

    Authors: Mandy Goldberg, Aimee A. D’Aloisio, Katie M. O’Brien, Shanshan Zhao and Dale P. Sandler
    Citation: Breast Cancer Research 2021 23:111
  21. The purpose of this study was to determine whether advanced quantitative magnetic resonance imaging (MRI) can be deployed outside of large, research-oriented academic hospitals and into community care settings...

    Authors: John Virostko, Anna G. Sorace, Kalina P. Slavkova, Anum S. Kazerouni, Angela M. Jarrett, Julie C. DiCarlo, Stefanie Woodard, Sarah Avery, Boone Goodgame, Debra Patt and Thomas E. Yankeelov
    Citation: Breast Cancer Research 2021 23:110
  22. Arm and shoulder problems (ASP), including lymphedema, were common among women with breast cancer in high-income countries before sentinel lymph node biopsy became the standard of care. Although ASP impair qua...

    Authors: Pauline Boucheron, Angelica Anele, Annelle Zietsman, Moses Galukande, Groesbeck Parham, Leeya F. Pinder, Therese M.-L. Andersson, Benjamin O. Anderson, Milena Foerster, Joachim Schüz, Isabel dos Santos Silva and Valerie McCormack
    Citation: Breast Cancer Research 2021 23:109
  23. Research on psychosocial stress and risk of breast cancer has produced conflicting results. Few studies have assessed this relation by breast cancer subtype or specifically among Black women, who experience un...

    Authors: Lauren E. Barber, Gary R. Zirpoli, Yvette C. Cozier, Lynn Rosenberg, Jessica L. Petrick, Kimberly A. Bertrand and Julie R. Palmer
    Citation: Breast Cancer Research 2021 23:108
  24. Breast cancer is a highly heterogeneous disease with multiple drivers and complex regulatory networks. Periostin (Postn) is a matricellular protein involved in a plethora of cancer types and other diseases. Po...

    Authors: Cédrik Labrèche, David P. Cook, John Abou-Hamad, Julia Pascoal, Benjamin R. Pryce, Khalid N. Al-Zahrani and Luc A. Sabourin
    Citation: Breast Cancer Research 2021 23:107
  25. Elevated mammographic breast density is a strong breast cancer risk factor with poorly understood etiology. Increased deposition of collagen, one of the main fibrous proteins present in breast stroma, has been...

    Authors: Clara Bodelon, Maeve Mullooly, Ruth M. Pfeiffer, Shaoqi Fan, Mustapha Abubakar, Petra Lenz, Pamela M. Vacek, Donald L. Weaver, Sally D. Herschorn, Jason M. Johnson, Brian L. Sprague, Stephen Hewitt, John Shepherd, Serghei Malkov, Patricia J. Keely, Kevin W. Eliceiri…
    Citation: Breast Cancer Research 2021 23:105
  26. In breast cancer, complex interactions between tumor cells and cells within the surrounding stroma, such as macrophages, are critical for tumor growth, progression, and therapeutic response. Recent studies hav...

    Authors: Emily A. Jesser, Nicholas J. Brady, Danielle N. Huggins, Patrice M. Witschen, Christine H. O’Connor and Kathryn L. Schwertfeger
    Citation: Breast Cancer Research 2021 23:104
  27. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that facilitates the adaptation of cancer cells to hypoxic conditions and may be prognostic of breast cancer recurrence. We evaluated the associat...

    Authors: Lindsay J. Collin, Maret L. Maliniak, Deirdre P. Cronin-Fenton, Thomas P. Ahern, Kristina B. Christensen, Sinna P. Ulrichsen, Per Damkier, Stephen Hamilton-Dutoit, Rami Yacoub, Peer M. Christiansen, Henrik Toft Sørensen and Timothy L. Lash
    Citation: Breast Cancer Research 2021 23:103
  28. Accumulating evidence has attracted attention to the androgen receptor (AR) as a biomarker and therapeutic target in breast cancer. We hypothesized that AR activity within the tumor has clinical implications a...

    Authors: Toru Hanamura, Jessica L. Christenson, Kathleen I. O’Neill, Emmanuel Rosas, Nicole S. Spoelstra, Michelle M. Williams and Jennifer K. Richer
    Citation: Breast Cancer Research 2021 23:102
  29. Increased breast cancer screening over the past four decades has led to a substantial rise in the diagnosis of ductal carcinoma in situ (DCIS). Although DCIS lesions precede invasive ductal carcinoma (IDC), th...

    Authors: Ali S. Ropri, Rebecca S. DeVaux, Jonah Eng, Sridar V. Chittur and Jason I. Herschkowitz
    Citation: Breast Cancer Research 2021 23:101
  30. Metastatic breast cancer (MBC) is incurable, with a 5-year survival rate of 28%. In the USA, more than 42,000 patients die from MBC every year. The most common type of breast cancer is estrogen receptor-positi...

    Authors: Sandra D. Scherer, Alessandra I. Riggio, Fadi Haroun, Yoko S. DeRose, H. Atakan Ekiz, Maihi Fujita, Jennifer Toner, Ling Zhao, Zheqi Li, Steffi Oesterreich, Ahmed A. Samatar and Alana L. Welm
    Citation: Breast Cancer Research 2021 23:100
  31. Tumour-infiltrating lymphocyte (TIL)-high breast tumours have a high rate of pathological complete response (pCR) with neoadjuvant chemotherapy. In our routine pathological diagnoses of biopsy specimens from p...

    Authors: Asumi Sakaguchi, Yoshiya Horimoto, Hiroko Onagi, Daiki Ikarashi, Takayuki Nakayama, Tetsuya Nakatsura, Hideo Shimizu, Kuniaki Kojima, Takashi Yao, Toshiharu Matsumoto, Kanako Ogura and Shigehisa Kitano
    Citation: Breast Cancer Research 2021 23:99
  32. Mechanical interactions between tumor cells and microenvironments are frequent phenomena during breast cancer progression, however, it is not well understood how these interactions affect Epithelial-to-Mesench...

    Authors: Kenneth F. Fuh, Robert D. Shepherd, Jessica S. Withell, Brayden K. Kooistra and Kristina D. Rinker
    Citation: Breast Cancer Research 2021 23:97
  33. Transcriptome sequencing has been broadly available in clinical studies. However, it remains a challenge to utilize these data effectively for clinical applications due to the high dimension of the data and th...

    Authors: Xiangning Chen, Daniel G. Chen, Zhongming Zhao, Justin M. Balko and Jingchun Chen
    Citation: Breast Cancer Research 2021 23:96
  34. Oestrogen receptor-positive (ER+) breast cancer is commonly treated using endocrine therapies such as aromatase inhibitors which block synthesis of oestradiol, but the influence of this therapy on the immune c...

    Authors: Jody Hazlett, Virginia Niemi, Aziz Aiderus, Katelyn Powell, Lyn Wise, Roslyn Kemp and Anita K. Dunbier
    Citation: Breast Cancer Research 2021 23:95
  35. Advancements in cancer therapeutics have resulted in increases in cancer-related survival; however, there is a growing clinical dilemma. The current balancing of survival benefits and future cardiotoxic harms ...

    Authors: Lathan Liou, Stephen Kaptoge, Joe Dennis, Mitul Shah, Jonathan Tyrer, Michael Inouye, Douglas F. Easton and Paul D. P. Pharoah
    Citation: Breast Cancer Research 2021 23:94
  36. Cancer metastasis is a complex process involving the spread of malignant cells from a primary tumor to distal organs. Understanding this cascade at a mechanistic level could provide critical new insights into ...

    Authors: Anastasia A. Ionkina, Gabriela Balderrama-Gutierrez, Krystian J. Ibanez, Steve Huy D. Phan, Angelique N. Cortez, Ali Mortazavi and Jennifer A. Prescher
    Citation: Breast Cancer Research 2021 23:93
  37. Many women with breast cancer also have a high likelihood of cardiovascular mortality, and while there are several cardiovascular risk prediction models, none have been validated in a cohort of breast cancer p...

    Authors: Nicole M. Leoce, Zhezhen Jin, Rebecca D. Kehm, Janise M. Roh, Cecile A. Laurent, Lawrence H. Kushi and Mary Beth Terry
    Citation: Breast Cancer Research 2021 23:91
  38. During pregnancy, the mouse mammary ductal epithelium branches and grows into the surrounding stroma, requiring extensive extracellular matrix (ECM) and tissue remodelling. It therefore shows parallels to canc...

    Authors: Ayman M. Ibrahim, Alan Bilsland, Steffen Rickelt, Joanna S. Morris and Torsten Stein
    Citation: Breast Cancer Research 2021 23:90
  39. Telomere maintenance is crucial for the unlimited proliferation of cancer cells and essential for the “stemness” of multiple cancer cells. TAZ is more extensively expressed in triple negative breast cancers (T...

    Authors: Lu Yang, Bo Wang, Xinyan Jiao, Can Zhou, Su Chen, Xiaoqian Gao, Wei Sun, Shaoran Song, Juan Li, Jie Liu, Yaochun Wang and Peijun Liu
    Citation: Breast Cancer Research 2021 23:89
  40. This study evaluated the ability of 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just ...

    Authors: Perrin E. Romine, Lanell M. Peterson, Brenda F. Kurland, Darrin W. Byrd, Alena Novakova-Jiresova, Mark Muzi, Jennifer M. Specht, Robert K. Doot, Jeanne M. Link, Kenneth A. Krohn, Paul E. Kinahan, David A. Mankoff and Hannah M. Linden
    Citation: Breast Cancer Research 2021 23:88
  41. In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR] 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR 0.757) co...

    Authors: Patrick Neven, Hope S. Rugo, Sara M. Tolaney, Hiroji Iwata, Masakazu Toi, Matthew P. Goetz, Peter A. Kaufman, Yi Lu, Nadine Haddad, Karla C. Hurt and George W. Sledge Jr.
    Citation: Breast Cancer Research 2021 23:87
  42. Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breas...

    Authors: Anna Morra, Maria Escala-Garcia, Jonathan Beesley, Renske Keeman, Sander Canisius, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Paul L. Auer, Annelie Augustinsson, Laura E. Beane Freeman, Heiko Becher, Matthias W. Beckmann, Sabine Behrens, Stig E. Bojesen…
    Citation: Breast Cancer Research 2021 23:86
  43. In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition. How these mutations aff...

    Authors: Jamie O. Brett, Laura M. Spring, Aditya Bardia and Seth A. Wander
    Citation: Breast Cancer Research 2021 23:85
  44. The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 ...

    Authors: Emanuela Ferraro, Joshua Z. Drago and Shanu Modi
    Citation: Breast Cancer Research 2021 23:84
  45. The heterogeneity of the breast tumor microenvironment (TME) may contribute to the lack of durable responses to immune checkpoint blockade (ICB); however, mouse models to test this are currently lacking. Prope...

    Authors: Jessica Castrillon Lal, Madeline G. Townsend, Anita K. Mehta, Madisson Oliwa, Eric Miller, Alaba Sotayo, Emily Cheney, Elizabeth A. Mittendorf, Anthony Letai and Jennifer L. Guerriero
    Citation: Breast Cancer Research 2021 23:83
  46. African American women have the highest risk of breast cancer mortality compared to other racial groups. Differences in tumor characteristics have been implicated as a possible cause; however, the tumor microe...

    Authors: Gieira S. Jones, Katherine A. Hoadley, Linnea T. Olsson, Alina M. Hamilton, Arjun Bhattacharya, Erin L. Kirk, Heather J. Tipaldos, Jodie M. Fleming, Michael I. Love, Hazel B. Nichols, Andrew F. Olshan and Melissa A. Troester
    Citation: Breast Cancer Research 2021 23:80
  47. The ovarian hormones estrogen and progesterone (EP) are implicated in breast cancer causation. A specific consequence of progesterone exposure is the expansion of the mammary stem cell (MSC) and luminal progen...

    Authors: Manish Ranjan, Oukseub Lee, Gannon Cottone, Elnaz Mirzaei Mehrabad, Benjamin T. Spike, Zexian Zeng, Shivangi Yadav, Robert Chatterton, J. Julie Kim, Susan E. Clare and Seema A. Khan
    Citation: Breast Cancer Research 2021 23:78

Annual Journal Metrics